Pharmaceutical Technology

FEBRUARY 15, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely.

Genetics 130

Genetics DNA Genome Genomics 130

Pharmaceutical Technology

FEBRUARY 14, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely. CRISPR Therapeutics is one of the leading patent filers for mammalian expression vector technologies.

In-Vivo 130

In-Vivo DNA Antibody Gene 130

XTalks

JANUARY 21, 2025

The liquid portion of the blood (serum or plasma) containing antibodies is separated and tested using the Liason Biotrin parvovirus B19 IgG plus test on a Liason XL analyzer. If parvovirus B19 antibodies are present, they bind to the chemicals and particular particles in the test, producing a light signal. Photo courtesy of BD.

FDA Approval 105

FDA Approval Manufacturing Development RNA 105

The Pharma Data

SEPTEMBER 11, 2021

Boehringer Ingelheim believes Twist’s ability to generate potent, diverse therapeutic antibodies by mining its comprehensive libraries, combined with our extensive capabilities and experience in drug discovery and development, will enable us to deliver breakthrough opportunities to patients,” said Clive R. Wood, Ph.D., About Twist Biopharma.

Antibody 52

Antibody DNA Containment Manufacturing 52

Pharmaceutical Technology

MARCH 9, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely. Sanofi and F. Hoffmann-La Roche are the other key patent filers in transgenic murine models.

In-Vivo 130

In-Vivo Antibody Genetics Gene 130

XTalks

JUNE 16, 2023

Cetuximab, an anti-epidermal growth factor receptor (anti-EGFR) antibody with FDA approval for metastatic colorectal cancer, is effective in conjunction with encorafenib. The test utilizes circulating cell-free DNA (cfDNA) isolated from plasma derived from the anti-coagulated peripheral whole blood of advanced cancer patients.

FDA Approval 97

FDA Approval Genome Genomics DNA 97

Pharmaceutical Technology

MAY 8, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely.

Antibody 147

Antibody Vaccination Vaccine Dermatology 147

Pharmaceutical Technology

MAY 8, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely. They are the smallest type of programmable nuclease.

Genetics 130

Genetics DNA Genetic Engineering Antibody 130

XTalks

SEPTEMBER 2, 2021

The AlzoSure Predict prognostic biomarker Alzheimer’s blood test detects levels of an unfolded conformational variant of the p53 protein in the blood using a proprietary antibody called U-p53AZ. It is known as the “guardian of the genome” given its central role in the DNA damage response. Diadem’s Alzheimer’s Blood Test.

Protein 105

Protein DNA Antibody Genome 105

pharmaphorum

SEPTEMBER 13, 2022

Further research led Ehrlich to develop his side-chain theory, that antibodies produced by white blood cells act as receptors on the cell membrane. 2012 – The 100,000 Genomics Project begins. Unlocking the secrets of the human genome has intrigued investigators for centuries. This was an entirely new approach to DNA research.

Genome Project 98

Genome Project Genomics Genome DNA 98

pharmaphorum

JULY 13, 2022

The first subject has now been given a dose of VERVE-101, in what is thought to be the first test in humans of an experimental CRISPR/Cas9 genome editing technique known as base editing. Through base editing, drugs replace single nucleotide in the DNA strand with another, without making double-strand breaks (DSBs) in the gene.

Gene Editing 98

Gene Editing Trials Drugs In-Vivo 98

Pharmaceutical Technology

MAY 15, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely.

Antibody 130

Antibody DNA Genome Genomics 130

Delveinsight

JULY 30, 2020

Roche bets USD 120 Million on UCB’s anti-tau Alzheimer’s antibody. The Swiss pharma, Roche, is handing over USD 120 million upfront for the right of UCB’s anti-tau antibody development. ‘Genome-tuning’ biotech Omega Therapeutics snags USD 85 Million. GlaxoSmithKline, the U.S.

Genome 52

Genome Genomics Antibody Gene 52

The Pharma Data

APRIL 8, 2021

Leadership in DNA damage response demonstrated in multiple presentations for AZD5305, a next-generation PARP1 selective inhibitor. Data for AZD5305 will demonstrate how the next wave of DNA damage response medicines can build on the success of PARP inhibitors, potentially allowing patients to stay on treatment longer.

DNA 52

DNA Medicine Genome Genomics 52

XTalks

NOVEMBER 30, 2023

The noteworthy candidate, EBT-101, is designed to eliminate HIV proviral DNA using CRISPR-Cas9 along with two guide RNAs (gRNAs). These dual gRNAs target three specific sites within the HIV genome, facilitating the removal of substantial portions of the viral DNA and minimizing the potential for viral escape.

FDA Approval 111

FDA Approval Gene Therapy Gene Clinical Trials 111

The Pharma Data

DECEMBER 2, 2020

Results show the protocol demonstrated a 30Gb+ yield of long DNA reads raw data of an E. The FMv8 protocol introduces a needle-aspirate-based, cell-resuspension step prior to cell lysis that boosts DNA recovery. Elsewhere around the globe: RevoluGen – U.K.-based Financial details of the agreement were not disclosed. in Mainland China.

Drugs 52

Drugs Gene Editing Genomics Genome 52

The Pharma Data

DECEMBER 3, 2020

For example, “Viral antigens and antibodies (typically IgM and IgG) become detectable at different periods during infection…and the detection time…depends on several parameters, such as viral features, individual patient variability and the applied test.” Other techniques are primed to replace it.

RNA 52

RNA Protein DNA Antibody 52

Cloudbyz

MARCH 6, 2024

Unlike traditional small molecule drugs, which are chemically synthesized, biologics are produced through complex biotechnological processes, often involving recombinant DNA technology. This allows for the creation of highly specific and targeted therapies that can modulate biological pathways with remarkable precision.

Gene 99

Gene Immune Response Manufacturing Gene Therapy 99

XTalks

NOVEMBER 7, 2022

Liquid biopsy tests in oncology involve isolating entities such as circulating tumor cells (CTC), circulating tumor DNA (ctDNA) and tumor-derived exosomes. These tumor-derived entities are used to derive genomic and proteomic data. The cfDNA that originates from tumors is called circulating tumor DNA (ctDNA).

Clinical Trials 98

Clinical Trials Clinical Trials Trials FDA Approval 98

Roots Analysis

SEPTEMBER 9, 2024

The rising demand for protein therapeutics, such as monoclonal antibodies and vaccines , is driving advancements in protein expression technology to ensure efficient and scalable production. This process initially involves transcription of DNA to messenger RNA (mRNA). The mRNA is then translated into to form functional proteins.

Protein 40

Protein Gene Production DNA 40

XTalks

OCTOBER 26, 2023

The Flu versus COVID-19: Virology and Vaccines SARS-CoV-2 versus Influenza Virology Viruses contain genetic material that can either be RNA or DNA. An RNA genome enables the genetic material to mutate more rapidly. While levels of neutralizing antibodies can be used to determine protection, it is not a defined universal criterion.

Vaccine 105

Vaccine Vaccination RNA Manufacturing 105

The Pharma Data

OCTOBER 14, 2020

VBL Therapeutics – The European Patent Office granted a patent to Israel-based VBL’s proprietary investigational anti-MOSPD2 monoclonal antibodies to treat inflammatory conditions. ERS Genomics – Ireland’s ERS Genomics signed an agreement with FASMAC Co., The patent is valid through 2038. Ltd of Japan.

Clinical Trials 52

Clinical Trials Clinical Trials Manufacturing In-Vivo 52

The Pharma Data

SEPTEMBER 2, 2021

Transforming treatment of advanced cancers with antibody drug conjugates (ADCs). Changing treatment paradigms with industry-leading PARP inhibitors and next-wave DNA damage response therapies. Antibody drug conjugates. Antibody drug conjugates. Abstract #P47.11. 8 September 2021. Borghaei, H. Abstract #P47.06.

Trials 52

Trials Medicine Antibody Clinical Trials 52

The Pharma Data

OCTOBER 14, 2020

Potential Development of Human Monoclonal Antibody Therapeutics to SARS-CoV-2. The research is part of an ongoing collaboration between Columbia University and Tonix that focuses on T cell and antibody responses to SARS-CoV-2 (CoV-2), the virus that causes COVID-19. CHATHAM, N.J., Ilya Trakht, Ph.D.,

Vaccine 40

Vaccine Vaccination Development Medicine 40

The Pharma Data

APRIL 30, 2021

a leading clinical-stage CRISPR genome editing biotechnology company, announced that they have entered into a collaboration and license agreement for the research and development of chimeric antigen receptor (CAR)-T cell therapeutics. AbbVie and Caribou Biosciences, Inc.,

Botox 40

Botox Production Development Cosmetics 40

The Pharma Data

OCTOBER 26, 2020

50%) with no EGFR or ALK genomic tumor aberrations. L1 expression with no EGFR or ALK genomic tumor aberrations at the IASLC 2020 North America Conference on Lung Cancer (NACLC). formerly known as Seattle Genetics, Inc.) Organon & Co. Merck continued to make progress on the Organon & Co.

Sales 40

Sales Vaccination Vaccine Production 40

XTalks

DECEMBER 24, 2020

From isolating SARS-CoV-2 in early January to sequencing its genome shortly thereafter and having a prototype vaccine against it within days, scientific process and progress have held steadfast throughout the pandemic. Most antibody drugs and vaccines have been developed to target parts of the spike protein. Drug Approvals.

Life Science 111

Life Science Vaccination Vaccine Gene 111

Pharmaceutical Technology

MARCH 9, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely.

Antibody 130

Antibody Hormones DNA Genome 130

Pharmaceutical Technology

MARCH 29, 2023

The government is giving Touchlight £14 million for commercial scale manufacturing of its “doggybone DNA” vector at its Hampton, London base. Randox is also gaining a £36 million investment to improve its manufacturing capacity for antibodies used across diagnostic tests.

Life Science 276

Life Science Manufacturing Gene Therapy Medicine 276